Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALXN1720 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| ALXN1720 | EXPERIMENTAL | Participants will receive a weight-based initial (loading) dose of ALXN1720 on Day 1, followed by weight-based maintenance treatment with ALXN1720 on Day 8 and once every week (Q1W) thereafter for a total of 26 weeks. Following this randomized controlled treatment (RCT) period, all participants will receive ALXN1720 in an open-label extension (OLE) period of 105 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo during the 26-week RCT period, after which they will enter the OLE period of the study and receive ALXN1720. |
| ALXN1720 Single Dose SC | EXPERIMENTAL | Participants will receive a single dose of ALXN1720 SC. |
| ALXN1720 Multiple Dose SC | EXPERIMENTAL | Participants will receive multiple doses of ALXN1720 SC. |
| ALXN1720 Single Dose SC + rHuPH20 | EXPERIMENTAL | Participants will receive a single dose of ALXN1720 SC in combination with rHuPH20. |
| ALXN1720 Single Dose IV | EXPERIMENTAL | Participants will receive a single dose of ALXN1720 IV. |
| Name | Type | Description |
|---|---|---|
| ALXN1720 | COMBINATION_PRODUCT | Combination product consisting of syringe prefilled with ALXN1720. |
| Placebo | COMBINATION_PRODUCT | Combination product consisting of syringe prefilled with placebo. |
| ALXN1720 SC | DRUG | ALXN1720 will be administered via SC route. |
| ALXN1720 IV | DRUG | ALXN1720 will be administered via IV route. |
| rHuPH20 | DRUG | rHuPH20 will be administered via SC route. |
| Placebo SC | DRUG | Placebo will be administered via SC route. |
| Placebo IV | DRUG | Placebo will be administered via IV route. |
Inclusion Criteria: * Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV * Positive serological test for autoantibodies against AChR Exclusion Criteria: * History of thymectomy, or any other ...
ALXN1720 is an investigational small molecule being studied for the treatment of generalized myasthenia gravis (gMG). It is currently in Phase 3 clinical development for this condition. The drug is administered subcutaneously and is being evaluated in a randomized, double-blind, placebo-controlled trial.
ALXN1720 is being developed by AstraZeneca PLC, a biopharmaceutical company traded on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the safety and efficacy of ALXN1720 in multiple patient populations.
ALXN1720 is in Phase 3 clinical development for generalized myasthenia gravis. The Phase 3 trial is active but not recruiting participants. Earlier Phase 1 studies of ALXN1720 have been completed in healthy volunteers and in participants with proteinuria.
ALXN1720 has been studied in several clinical trials. The Phase 3 trial, NCT05556096, is evaluating the drug in adults with generalized myasthenia gravis. Completed Phase 1 trials include NCT04920370 in healthy subjects and NCT05314231 in participants with proteinuria.
ALXN1720 is a small molecule therapeutic agent. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being investigated for its potential effects in neurological and renal conditions.
ALXN1720 is a distinct investigational drug being developed by AstraZeneca. It is not known to be the same as any other approved or investigational medication. Its unique mechanism and chemical structure differentiate it from existing therapies for generalized myasthenia gravis.